Peyronie's Disease News and Research

RSS
Of all penile diseases, Peyronie’s disease represents one with often devastating physical and psychological consequences on affected individuals. Also known as induratio penis plastica, this is an incurable, fibrotic (scarring) disease that results in penile curvature, erectile dysfunction and subsequent coital failure.
Study suggests erectile dysfunction in young men may be more prevalent than previously thought

Study suggests erectile dysfunction in young men may be more prevalent than previously thought

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Health Canada approves XIAFLEX for Dupuytren's contracture

Health Canada approves XIAFLEX for Dupuytren's contracture

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Actelion, Auxilium partner to develop and commercialize XIAFLEX

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

Auxilium reports net revenues of $66.7 million for third quarter 2011

Auxilium reports net revenues of $66.7 million for third quarter 2011

Auxilium second quarter net loss decreases to $5.1 million

Auxilium second quarter net loss decreases to $5.1 million

Penile extenders represent an effective lengthening method for men

Penile extenders represent an effective lengthening method for men

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

BioSpecifics 2010 net loss decreases to $1.5 million

BioSpecifics 2010 net loss decreases to $1.5 million

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

BioSpecifics Technologies third quarter net loss increases to $0.5 million

BioSpecifics Technologies third quarter net loss increases to $0.5 million

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

Auxilium commences dosing in global XIAFLEX phase III program for Peyronie's disease

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

U.S. Marshals seize FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices

U.S. Marshals seize FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices

BioSpecifics' partner Auxilium provides update on XIAFLEX

BioSpecifics' partner Auxilium provides update on XIAFLEX

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M